<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02035215</url>
  </required_header>
  <id_info>
    <org_study_id>13-OM-8302</org_study_id>
    <nct_id>NCT02035215</nct_id>
  </id_info>
  <brief_title>Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia</brief_title>
  <official_title>Efficacy and Safety of Co-administration of Omacor Plus Atorvastatin Compared With Atorvastatin Monotherapy in Patients With Type Ⅱb Dyslipidemia: a Multicenter, Double-blind, Randomized, Active-controlled, Parallel, Phase Ⅲ Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuhnil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kuhnil Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of combination therapy of
      omega-3-acids ethylesters 90/Atorvastatin calcium in type Ⅱb hyperlipidemia
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean percent change of Triglyceride(TG)</measure>
    <time_frame>from baseline at week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean percent change of Triglyceride(TG)</measure>
    <time_frame>from baseline at week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percent change of Total Cholesterol(TC), LDL-C, HDL-C</measure>
    <time_frame>from baseline at week 4,8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hyperlipidemia, Familial Combined</condition>
  <arm_group>
    <arm_group_label>Atorvastatin 20mg, Omega-3-acids ethylesters 90 4g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin calcium 20mg, Omega-3-acids ethylesters 90 4g: po, q.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 20mg, Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Atorvastatin calcium 20mg, Placebo for Omega-3-acids ethylesters 90 4g: po, q.d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20mg</intervention_name>
    <arm_group_label>Atorvastatin 20mg, Omega-3-acids ethylesters 90 4g</arm_group_label>
    <arm_group_label>Atorvastatin 20mg, Placebo</arm_group_label>
    <other_name>Lipitor 20mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3-acids ethylesters 90 4g</intervention_name>
    <arm_group_label>Atorvastatin 20mg, Omega-3-acids ethylesters 90 4g</arm_group_label>
    <other_name>Omacor Soft Capsule 4g</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo(Omega-3-acids ethylesters 90)</intervention_name>
    <arm_group_label>Atorvastatin 20mg, Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LDL≥160mg/dl, 200mg/dl≤TG&lt;500mg/dl

          -  In the case of smokers, he agrees should be smoke-free

          -  In the case of women of childbearing age, urine pregnancy test must be negative

        Exclusion Criteria:

          -  Patients with acute artery disease within 3 months

          -  History of revascularization procedure or aneurism operation within 6months

          -  Patients with myopathy, rhabdomyolysis

          -  Patients with pancreatitis

          -  Patients with HIV positive

          -  History of malignant tumor within 2 years

          -  Patients must be treated with medications prohibited for concomitant use during study
             period

          -  Patients with uncontrolled hypertension(SBP&gt;180mmHg or DBP&gt;110mmHg)

          -  Serum Creatinine&gt;1.2mg/dl(female), &gt;1.4mg/dl(male)

          -  AST or ALT &gt; 2X ULN

          -  CPK &gt; 2X ULN

          -  Patients with galactose intolerance or Lapp lactase deficiency, glucose-galactose
             malabsorption

          -  Allergy or Hypersensitive to investigational drug

          -  History of drug or alcohol abuse within 2 years

          -  In the case of smokers, who do not intend to non smoking

          -  Women with pregnant, breast-feeding

          -  Patients treated with any investigational drugs within 1 month at the time consents
             are obtained

          -  Not eligible to participate for the study at the discretion of investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Seog Seo, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hee Kyoung Cheon, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uijongbu St. Mary`s Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang-Ho Jo, Ph.d.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mi-Seung Shin, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kuhnil Clinical Research Team</last_name>
    <phone>+82-2-2175-9760</phone>
    <email>jmhong@kuhnil.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang, Gyeonggi</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uijongbu St. Mary`s Hospital</name>
      <address>
        <city>Uijongbu, Gyeonggi</city>
        <zip>480-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2014</study_first_submitted>
  <study_first_submitted_qc>January 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2014</study_first_posted>
  <last_update_submitted>March 19, 2014</last_update_submitted>
  <last_update_submitted_qc>March 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperlipidemia, Familial Combined</keyword>
  <keyword>Omega 3 acids ethylesters 90</keyword>
  <keyword>Atorvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipidemia, Familial Combined</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

